Overview

Study to Evaluate Efficacy and Safety of Entelon 50mg in Patients With Non-Proliferative Diabetic Retinopathy

Status:
Not yet recruiting
Trial end date:
2024-12-16
Target enrollment:
Participant gender:
Summary
This clinical trial is a multi-center, double-blind, randomized, placebo controlled , parallel design, superiority, phase 4 study to evaluate the efficacy and safety of Entelon 50mg in 396 patients with non-proliferative diabetic retinopathy.
Phase:
Phase 4
Details
Lead Sponsor:
Hanlim Pharm. Co., Ltd.